MLYS (US) share price forecast & AI signal — Mineralys Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in MLYS
Mineralys Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Mineralys Therapeutics, Inc
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $15.33 |
| 2026-11-05 | $15.24 |
| 2026-11-04 | $17.00 |
| 2026-11-03 | $15.99 |
| 2026-11-02 | $15.55 |
| 2026-10-30 | $18.18 |
| 2026-10-29 | $21.24 |
MLYS FAQ
Is Mineralys Therapeutics, Inc (MLYS) a buy or sell this week?
The ACE Stock Bots machine-learning model rates MLYS a BUY for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for MLYS?
Every week the model scores MLYS across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.